SpectraCure
SpectraCure is a Swedish medical technology company based in Lund that develops a proprietary photodynamic therapy system for treating localized prostate cancer. Its platform combines a laser-based treatment device, a photosensitive drug, and patented dose-control software under the Q-PRO and IDOSE® names, with the same core technology designed to be adaptable to other solid tumors.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueLaser-based medical device components used to deliver interstitial PDT treatment.
Patented IDOSE® software that manages light dose and treatment precision.
Clinical studies and evidence generation for prostate cancer indications.
Work to enable future series production and product launch.
Customers
SpectraCure’s direct customers are not end patients but healthcare providers, clinical investigators, and ultimately hospitals and specialist cancer centers that would adopt the Q-PRO® system after regulatory approval. In the current development phase, the company also works with research partners, reference clinics, and technology collaborators that support clinical validation and industrialization.
They run the prostate cancer studies and generate the clinical evidence needed for approval and adoption.
Future buyers of the Q-PRO® system for focal treatment of localized prostate cancer.
They support product development, industrialization, and future manufacturing readiness.
Potential partners for broader market access and technology monetization.
Strategy
SpectraCure’s strategy is to build clinical evidence for Q-PRO® in recurrent and primary localized prostate cancer, then use that evidence to support regulatory approval and commercialization. The company is also preparing the product for series production and working with external technology partners to make the system manufacturable at scale.
Approval and adoption depend on demonstrating safety and efficacy in well-run studies.
Commercial launch requires market authorization in North America and Europe.
The system must be ready for series production before commercialization.
The same PDT approach may be adapted to other solid tumors over time.
Geography
SpectraCure is headquartered in Lund, Sweden, and its development work is anchored there. Its clinical and commercialization strategy is focused on North America and Europe, while industrialization work involves partners in the Netherlands and Switzerland.
Risks
SpectraCure’s main risks are tied to clinical development, regulatory approval, and the ability to secure commercialization or licensing agreements. As a development-stage medtech company, it also faces competition from alternative prostate cancer treatments and depends on external partners for parts of product development and future market access.
- Clinical development riskImpact: CriticalLikelihood: High
The business depends on proving that Q-PRO® is safe and effective in patient studies.
Exposure: Recurrent and primary localized prostate cancer trials
- Licensing and commercialization riskImpact: HighLikelihood: High
Future monetization may rely on licensing or partner agreements on acceptable terms.
- Regulatory approval riskImpact: HighLikelihood: Medium
Commercial launch cannot occur without market authorization in target regions.
Exposure: North America and Europe
- Competition from alternative treatmentsImpact: MediumLikelihood: Medium
Other prostate cancer therapies may be more established, better funded, or easier to adopt.
- Partner dependency riskImpact: MediumLikelihood: Medium
Industrialization and development rely on external collaborators and reference clinics.
Accounting
Judgemental itemsAdministrative services are the main customer revenue item and must be recognized correctly.
Impact: Affects reported other operating income
Research and innovation grants are recognized over the period they compensate.
Impact: Affects timing of other operating income
Administrative service sales to related parties require market-based pricing and disclosure.
Impact: Affects comparability of revenue and margins
Lease accounting shifts cash flow classification without changing total cash flow.
Impact: Affects operating vs financing cash flow presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
IceCure Medical Ltd.
ICCM · Surgical & Medical Instruments & Apparatus
Spectral AI, Inc.
MDAI · Surgical & Medical Instruments & Apparatus
NovoCure Ltd
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
Sensus Healthcare, Inc.
SRTS · Surgical & Medical Instruments & Apparatus
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
Spectral Capital Corp
FCCN · Services-Computer Processing & Data Preparation
SPECTRAL CAPITAL Corp is a U.S.-based technology company organized around intellectual property development, software commercialization, and technology acquisitions.
Last updated: 24/09/2026